Kyowa Kirin International has announced final results from the German MINT study evaluating mogamulizumab in patients with MF ...

Northwest Biotherapeutics and NHS Blood and Transplant have agreed a collaboration to support production of DCVax-L, a ...

Alnylam UK Limited has welcomed a Scottish Medicines Consortium decision to accept vutrisiran for adults with ATTR‑CM, enabling eligible patients to access AMVUTTRA through NHS ...

Laverock Therapeutics has announced new in vivo programmes spanning CAR‑T and genetic medicine, expanding its therapeutic ...

Mums whose babies developed life‑threatening sepsis and meningitis from group B streptococcus are urging pregnant women to ...

Atrogi has announced positive human data for ATR‑258, its first‑in‑class oral GRK2‑biased β2‑adrenergic modulator designed to improve muscle function and body composition. In an 8‑week ...

AbbVie has received European Commission approval for Rinvoq to treat active polyarticular juvenile idiopathic arthritis in ...

Kither Biotech has started dosing patients in its phase 1b / 2a clinical study of KIT2014 in adults with moderate to severe ...

Teva has received US FDA approval for DEGEVMA (denosumab‑adet), a biosimilar to Xgeva, marking a further step in its Pivot to Growth strategy. The product is authorised across all Xgeva indications, ...

Neuraxpharm and Minoryx have announced that the European Commission has granted marketing authorisation under exceptional ...

NICE has issued final draft guidance recommending Tryngolza (olezarsen) for adults in England and Wales with genetically confirmed familial chylomicronaemia syndrome, but only when response to diet ...

Maternity care is one of the most fundamental components of any healthcare system. It shapes not only the health of mothers ...